Due to supply issues the MHRA (UK government) has asked all prescribers to refrain from prescribing semaglutide for obesity management, in order to preserve current scarce supplies for diabetic patients.
The supply issues are expected to continue until mid 2024, but we will of course keep our patients updated when this guidance is updated.
Our doctors remain happy to discuss alternative pharmaceutical or traditional interventions for weightloss.